| Autor: |
Herrera, Mercedes, Pretelli, Giulia, Desai, Jayesh, Garralda, Elena, Siu, Lillian L., Steiner, Thiago M., Au, Lewis |
| Zdroj: |
Trends in Cancer; October 2024, Vol. 10 Issue: 10 p893-919, 27p |
| Abstrakt: |
Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action.Manipulating bsAb structures allows generation of multiple formats to optimize molecular function for specific clinical contexts.Thus far, a total of seven bsAbs have received regulatory approval for use in hematological malignancies and four in select solid tumors, with notable clinical efficacy.The toxicities associated with the use of bsAbs need bespoke management strategies and expertise in clinical use.Understanding mechanisms of resistance to bsAbs is crucial to rational combination regimens or sequencing with other therapeutics to improve patient outcomes. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
